CN Patent

CN106938039A — 眼睑下垂的治疗药物

Assigned to Individual · Expires 2017-07-11 · 9y expired

What this patent protects

本发明涉及眼睑下垂的治疗药物，医药技术领域，在于解决眼睑下垂的衰老性问题，通过对眼睑下垂的病理分析后对症下药，采取适合的中药组合成治疗药物，其特征是按下面各中药质量份比组合而成：柏子仁15份、生姜10份、肉苁蓉15份、木瓜50份、枸杞子30份、陈皮15份、淮山药12份、荔枝肉12份、黄芩15份、杜仲12份、板兰根15份、熟地15份、金钱草12份、昆布10份、甘草7份。

USPTO Abstract

本发明涉及眼睑下垂的治疗药物，医药技术领域，在于解决眼睑下垂的衰老性问题，通过对眼睑下垂的病理分析后对症下药，采取适合的中药组合成治疗药物，其特征是按下面各中药质量份比组合而成：柏子仁15份、生姜10份、肉苁蓉15份、木瓜50份、枸杞子30份、陈皮15份、淮山药12份、荔枝肉12份、黄芩15份、杜仲12份、板兰根15份、熟地15份、金钱草12份、昆布10份、甘草7份。

Drugs covered by this patent

oxymetazoline-hydrochloride (OXYMETAZOLINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN106938039A
Jurisdiction: CN
Classification: —
Expires: 2017-07-11
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.